Account
Insider Insights
01.02.2022
UK NICE recommends selective laser therapy

According to updated guidelines published by NICE, patients newly diagnosed with glaucoma and ocular...

Read more
Insider Insights
01.02.2022
New restrictions for Prolia

The study showed that 20 - 25% of all prescriptions for the drug were not in line with the drug's au...

Read more
Insider Insights
01.02.2022
Increasing prescribing controls on new medicines

According to data from the Ministry of Health 65.1% of medicines admitted to reimbursement in 2021 w...

Read more
Insider Insights
01.02.2022
Prescribing controls on new medicines

The Ministry of Health reports that 65.1% of medicines admitted to reimbursement in 2021 were subjec...

Read more
Articles
05.01.2022
Orphan Drugs and Diseases: 101

This article discusses updates to the orphan drugs and diseases landscapes, the challenges and incen...

Read more
News
15.12.2021
PMA Insights: Week 51 2021

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
Publications
03.12.2021
Pricing and reimbursement policies for digital the

Digital therapeutics (DTx) is a category of digital health, which is defined as products that delive...

Read more
News
13.10.2021
PMA Insights: Week 41

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
Articles
27.09.2021
Access for rare disease treatments

Innovative therapies for rare diseases may only be available in a select number of countries in Euro...

Read more
News
09.09.2021
PMA Insights: Week 39 2021

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.